{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:33:21Z","timestamp":1761744801549,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejps.2018.08.026","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T05:23:33Z","timestamp":1535001813000},"page":"188-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: In vitro-in silico approach"],"prefix":"10.1016","volume":"124","author":[{"given":"Djordje","family":"Medarevi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Cviji\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Dobri\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miodrag","family":"Mitri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Djuri\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Ibri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.08.026_bb0005","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.08.026_bb0010","series-title":"Profiles of Drug Substances, Excipients, and Related Methodology","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/bs.podrm.2015.01.004","article-title":"Valsartan","volume":"vol. 40","author":"Ardiana","year":"2015"},{"key":"10.1016\/j.ejps.2018.08.026_bb0015","article-title":"Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs","author":"B\u00e4ckman","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"year":"2008","series-title":"Kollidon \u00ae: Polyvinylpyrrolidone Excipients for the Pharmaceutical Industry","author":"Buhl\u00ebr","key":"10.1016\/j.ejps.2018.08.026_bb0020"},{"key":"10.1016\/j.ejps.2018.08.026_bb0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijpharm.2012.05.076","article-title":"Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique","volume":"434","author":"Cao","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0030","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.carbpol.2013.12.047","article-title":"Valsartan inclusion by methyl\u2011\u03b2\u2011cyclodextrin: thermodynamics, molecular modelling, tween 80 effect and evaluation","volume":"103","author":"Chadha","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejps.2018.08.026_bb0035","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s13318-015-0290-5","article-title":"Formulation and pharmacokinetic evaluation of polymeric dispersions containing valsartan","volume":"41","author":"Chella","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.08.026_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0278-6915(00)00136-8","article-title":"Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats","volume":"39","author":"DeSesso","year":"2001","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejps.2018.08.026_bb0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1208\/s12249-010-9385-0","article-title":"Preparation and bioavailability assessment of SMEDDS containing valsartan","volume":"11","author":"Dixit","year":"2010","journal-title":"AAPS PharmSciTech"},{"author":"European Medicines Agency (EMA)","key":"10.1016\/j.ejps.2018.08.026_bb0050"},{"key":"10.1016\/j.ejps.2018.08.026_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002280050259","article-title":"Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man","volume":"52","author":"Flesch","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"author":"Food and Drug Administration (FDA)","key":"10.1016\/j.ejps.2018.08.026_bb0060"},{"key":"10.1016\/j.ejps.2018.08.026_bb0065","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10717544.2014.923066","article-title":"Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study","volume":"23","author":"Gora","year":"2016","journal-title":"Drug Deliv."},{"issue":"Suppl. 1","key":"10.1016\/j.ejps.2018.08.026_bb0070","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","author":"Israili","year":"2000","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejps.2018.08.026_bb0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.08.026_bb0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2018.08.026_bb0085","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.xphs.2015.11.034","article-title":"Physiologically based absorption modeling to impact biopharmaceutics and formulation strategies in drug development-industry case studies","volume":"105","author":"Kesisoglou","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.08.026_bb0090","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3109\/03639045.2013.807279","article-title":"Evaluation of different screening methods to understand the dissolution behaviors of amorphous solid dispersions","volume":"40","author":"Lee","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0095","first-page":"2745","article-title":"Soluplus\u00ae\/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan","volume":"9","author":"Lee","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2018.08.026_bb0100","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1023\/A:1018917729477","article-title":"Dissolution modeling: factors affecting the dissolution rates of polydisperse powders","volume":"10","author":"Lu","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.08.026_bb0105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/03639045.2015.1104347","article-title":"Solid-state characterization of Felodipine-Soluplus amorphous solid dispersions","volume":"42","author":"Lu","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2012.12.025","article-title":"Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state","volume":"441","author":"Ma","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s002280050317","article-title":"Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects","volume":"52","author":"M\u00fcller","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.08.026_bb0120","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1208\/s12249-015-0388-8","article-title":"Pharmacokinetic evaluation of improved oral bioavailability of valsartan: proliposomes versus self-nanoemulsifying drug delivery system","volume":"17","author":"Nekkanti","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2018.08.026_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4196\/kjpp.2017.21.1.107","article-title":"Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: a case study of caffeine and ciprofloxacin","volume":"21","author":"Park","year":"2017","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejps.2018.08.026_bb0130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10928-009-9139-3","article-title":"Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data","volume":"36","author":"Poirier","year":"2009","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2018.08.026_bb0135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijbiomac.2017.04.067","article-title":"In vitro and in vivo evaluation of gastro-retentive carvedilol loaded chitosan beads using Gastroplus\u2122","volume":"102","author":"Praveen","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejps.2018.08.026_bb0140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10847-009-9595-9","article-title":"Solid state characterization of the inclusion complex of valsartan with methyl \u03b2-cyclodextrin","volume":"65","author":"Pravin","year":"2009","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.ejps.2018.08.026_bb0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2014.04.048","article-title":"Investigation of drug-polymer interaction in solid dispersions by vapour sorption methods","volume":"469","author":"Pun\u010dochov\u00e1","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijpharm.2015.02.035","article-title":"Identifying the mechanisms of drug release from amorphous solid dispersions using MRI and ATR-FTIR spectroscopic imaging","volume":"483","author":"Pun\u010dochov\u00e1","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2014.01.001","article-title":"Enhanced intestinal permeability and oral bioavailability of enalapril maleate upon complexation with the cationic polymethacrylate Eudragit E100","volume":"55","author":"Ram\u00edrez-Rigo","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.08.026_bb0160","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.carbpol.2014.01.027","article-title":"Solid dispersion of efavirenz in PVP K-30 by conventional solvent and kneading methods","volume":"104","author":"Santos Alves","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejps.2018.08.026_bb0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejpb.2013.10.005","article-title":"Supersaturation, nucleation, and crystal growth during single- and biphasic dissolution of amorphous solid dispersions: polymer effects and implications for oral bioavailability enhancement of poorly water soluble drugs","volume":"86","author":"Sarode","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0170","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.powtec.2012.12.038","article-title":"Soluplus\u00ae: a novel polymeric solubilizer for optimization of carvedilol solid dispersions: formulation design and effect of method of preparation","volume":"237","author":"Shamma","year":"2013","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejps.2018.08.026_bb0175","first-page":"1","article-title":"On the inherent properties of Soluplus\u00ae and its application in ibuprofen solid dispersions generated by microwave-quench cooling technology","author":"Shi","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2018.08.026_bb0180","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3109\/03639045.2012.704379","article-title":"Thermal behavior and phase identification of Valsartan by standard and temperature-modulated differential scanning calorimetry","volume":"39","author":"Skotnicki","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0185","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.clinthera.2005.06.014","article-title":"Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis","volume":"27","author":"Smith","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2018.08.026_bb0190","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.addr.2016.01.012","article-title":"Amorphous solid dispersions: rational selection of a manufacturing process","volume":"100","author":"Vasconcelos","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.08.026_bb0195","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ejpb.2013.09.007","article-title":"Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs","volume":"85","author":"Vo","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0200","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1208\/s12248-015-9727-7","article-title":"Development of a novel oral cavity compartmental absorption and transit model for sublingual administration: illustration with zolpidem","volume":"17","author":"Xia","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2018.08.026_bb0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/10717544.2014.903012","article-title":"Enhanced dissolution and oral bioavailability of valsartan solid dispersions prepared by a freeze-drying technique using hydrophilic polymers","volume":"23","author":"Xu","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2018.08.026_bb0210","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1124\/dmd.105.008938","article-title":"Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the Angiotensin II AT1-receptor, in humans","volume":"34","author":"Yamashiro","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.08.026_bb0215","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2011.10.053","article-title":"Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes","volume":"422","author":"Yan","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0225","first-page":"1285","article-title":"Increased dissolution and oral absorption of itraconazole\/Soluplus extrudate compared with itraconazole nanosuspension","volume":"85","author":"Zhang","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.08.026_bb0230","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijpharm.2014.07.024","article-title":"Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths","volume":"473","author":"Zhang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.08.026_bb0235","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/jps.24373","article-title":"Prospective predictions of human pharmacokinetics for eighteen compounds","volume":"104","author":"Zhang","year":"2015","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718303919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718303919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:46:32Z","timestamp":1760528792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718303919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":46,"alternative-id":["S0928098718303919"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.08.026","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: In vitro-in silico approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}